COST UTILITY ANALYSIS PADA PASIEN DIABETES MELLITUS TIPE 2: INTEGRASI GULA DARAH, KOMORBIDITAS, BIAYA DAN KUALITAS HIDUP DALAM PENGAMBILAN KEPUTUSAN KLINIS
DOI:
https://doi.org/10.36387/jiis.v10i2.2796Keywords:
Type 2 Diabetes Mellitus, Quality of Life, Cost Utility Analysis (CUA), Comorbidities, Medical CostsAbstract
Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent chronic diseases in Indonesia and imposes a significant burden on healthcare costs. This study aimed to perform a Cost Utility Analysis (CUA) among T2DM patients by integrating blood glucose levels, comorbidities, direct medical costs, and quality of life. The research applied a cross-sectional design with prospective data collection using a convenience sampling technique. Quality of life was measured using the EQ-5D-5L questionnaire, while blood glucose levels, comorbidities, and direct medical costs were obtained from hospital medical records. Data analysis included descriptive statistics, Chi-Square tests, Logistic Regression analysis, and calculation of the utility index. The results showed that 38% of patients had good quality of life and 62% had poor quality of life, with an average utility index score of 0.5175. Random blood glucose levels of ≥200 mg/dL were found in 56% of respondents, while 44% had levels <200 mg/dL. Comorbidities were present in 52% of patients, while 48% had none. The median direct medical cost was IDR 425,500, with 62% categorized as high-cost and 38% as low-cost. Bivariate analysis revealed significant relationships between comorbidities, blood glucose levels, and direct medical costs with quality of life (p < 0.05). However, multivariate analysis showed that only blood glucose levels remained significant (p = 0.006). In conclusion, the overall quality of life of T2DM patients was generally poor, and blood glucose control was identified as the most influential independent factor affecting quality of life.
References
1. Artini KS, Listyani TA. Analisis efektivitas biaya dan terapi terhadap kualitas hidup pasien diabetes mellitus tipe 2 rawat jalan di Rumah Sakit X, Jawa Tengah. Pharmasipha: Pharm J Islam Pharm. 2024;8(1).
2. Webber S. International Diabetes Federation. Diabetes Res Clin Pract. 2021;102:147–148.
3. Ministry of Health Indonesia. Laporan Tahunan Kesehatan Indonesia 2022. Jakarta: Kementerian Kesehatan RI; 2022.
4. Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health. 2015 Mar;18(2):308–314.
5. EuroQol Group. EQ-5D User Guide [Internet]. 2019 [cited 2025 Jan 10]. Available from: https://euroqol.org.
6. Andayani TM, Dwi E, Susi AK, Rifki R. Metode untuk memperkirakan willingness-to-pay per quality adjusted life year sebagai cost effectiveness threshold. J Manaj Pelayanan Farm. 2017;7(3).
7. Yumassik AM, Riza A, Eka K, Akhmad R, Soraya, Welinda DA, et al. Korelasi antara kadar gula darah dengan kualitas hidup pasien diabetes melitus di fasilitas pelayanan kesehatan primer. J Insan Farm Indones. 2022;5(2).
8. Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014.
9. Luo N, Wang P, Fu AZ, Johnson JA. EQ-5D-5L norms and validation in the general population of China. Value Health Reg Issues. 2017;12:190–195.
10. Pribadi F, Permana I. Analysis of the cost-effectiveness of antidiabetic drugs among self paid participant of the Indonesia National Security Service (NSS) with type 2 diabetes mellitus. Int J Med Public Health. 2018;8(3):108–111.
11. Yang W, Dall TM, Beronjia K, et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928.
12. Wang W, McGowan P, Lin L. Cost-effectiveness of intensive blood glucose control with metformin in overweight type 2 diabetes patients in China. Pharmacoeconomics. 2016;34(2):179–90.
13. Ilahi FS, Aprilia TN, Yumassik AM, Wahyuni A. Evaluasi pengelolaan penyimpanan sediaan farmasi di gudang Instalasi Farmasi RSIA Ibunda Pelaihari. Jurnal Farmasi Insan Farmasi Indonesia. 2023;6(3):165–74.
14. Alshammari T, Aljadhey H, Mahmoud M. Cost-utility analysis of diabetes treatments: comparing insulin glargine vs NPH insulin in type 2 diabetes. Value Health Reg Issues. 2017;13:21–25
15. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2016;117:48–54.
16. Sari KP, Astuti YP. Kualitas hidup pasien diabetes mellitus berdasarkan EQ-5D di Puskesmas Kota Surabaya. J Pharm Sci Clin Res. 2019;4(2):89–96.
17. Kusuma AS, Permatasari K. Cost utility analysis terapi insulin pada pasien diabetes mellitus tipe 2. J Ilmu Kefarm Indones. 2022;20(1):12–21.
18. Dilla T, Reviriego J, Paz S. Cost-utility analysis of dulaglutide versus insulin glargine in type 2 diabetes patients. Value Health. 2016;19(3):A166.
19. Sari Y, Isworo A, Upoyo AS, et al. Health-related quality of life in younger and older adults with T2DM in Indonesia. Health Qual Life Outcomes. 2021;19(1):124.
20. Rumana NA, Sitoayu L, Sa’pang M. Correlation of fasting blood sugar with QoL in T2DM. INOHIM J. 2018;6(2):41–45.
21. Rustandi T, Yumassik AM, Ilahi FS, Alfian R, Prihandiwati E, Susanto Y, et al. Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics. Front Pharmacol. 2024;15:1428755.
22. Isnani N, Muliyani, Zaini M, Riyadi MA. Analisis efektivitas biaya (cost effectiveness) penggunaan antidiabetes oral kombinasi pada pasien diabetes melitus tipe II rawat jalan di RSUD Dr. H. Moch. Ansari Saleh Banjarmasin. Jurnal Insan Farmasi Indonesia. 2021 Mei;4(1):103–110
Downloads
Published
Issue
Section
License
Copyright (c) 2025 JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
